BAY1082439
Based on 1 publication(s) in Google Scholar
BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.35%
- CAS No.: 1375469-38-7
- 화학식: C25H30N6O5
- 분자량:494.54
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
HY-B0215
AcetylcysteineMucolytic Agent -
HY-15244
AlpelisibPI3Kα Inhibitor -
HY-101562
InavolisibPI3Kα Inhibitor -
HY-101272
GDC-0326PI3Kα Inhibitor -
HY-100886R
BAY1082439 (Standard)PI3Kα/β/δ Inhibitor -
HY-12285
Serabelisibp110α Inhibitor -
HY-70063
BuparlisibPI3K Inhibitor -
HY-50094
PictilisibPI3Kα/δ Inhibitor -
HY-107834
PIK-75DNA-PK/p110α Inhibitor -
HY-50847
ZSTK474Autophagy Inducer -
HY-10344
AZD 6482PI3Kβ Inhibitor -
HY-12036
GSK1059615Apoptosis Inducer
Publications Citing Use of MedChemExpress (MCE) BAY1082439
More
Biological Activity
제품 설명
IC50 & Target
[1]|
PI3Kα |
PI3Kβ |
PI3Kδ |
In Vitro
BAY1082439 is a highly selective PI3Kα/α-balanced inhibitor. BAY1082439 has an IC50 ratio of 1:3 in biochemical assays of PI3Kα (4.9 nM) vs. PI3Kα (15.0 nM), and >1000-fold selectivity against mTOR kinase[1].
BAY1082439 (0.1-1 μM; 72 hours) is more effective than PI3Kα- and/or PI3Kβ-selective inhibitors in blocking PTEN-null prostate cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC3 and LNCaP cells (PTEN-null human prostate cancer cell lines)
-
Concentration:0.1, 0.33, 1, 3.3, 10 μM
-
Incubation Time:72 hours
-
Result:Efectively inhibited cell growth by blocking the G1/S cell cycle transition and by inducing apoptosis.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pten conditional knockout mouse model (Pb-Cre+;PtenL/L, CP model)[2]
-
Dosage:75 mg/kg
-
Administration:P.o.; daily for 4 weeks
-
Result:Significantly decreased tumor size and P-AKT staining, nearly normal luminal architecture, and a significant reduction of Ki67-positive cells. Significantly inhibit the human prostate cancer growth.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1375469-38-7
-
Appearance Solid
-
분자량 494.54
-
화학식 C25H30N6O5
-
Color White to off-white
-
SMILES
O=C(C1=CC=CN=C1C)NC2=NC3=C(C=CC(OC[C@H](O)CN4CCOCC4)=C3OC)C5=NCCN25
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
용액&용해도
In Vitro:
0.1 M HCl : 16.67 mg/mL (33.71 mM; ultrasonic and warming and heat to 60°C)
DMSO : 5 mg/mL (10.11 mM; ultrasonic and adjust pH to 5 with HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 25 mg/mL (50.55 mM); Suspended solution; Need ultrasonic
순도&문서
-
Data Sheet (278 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 0.1 M HCl | 1 mM | 2.0221 mL | 10.1104 mL | 20.2208 mL | 50.5520 mL |
| 5 mM | 0.4044 mL | 2.0221 mL | 4.0442 mL | 10.1104 mL | |
| 10 mM | 0.2022 mL | 1.0110 mL | 2.0221 mL | 5.0552 mL | |
| 0.1 M HCl | 15 mM | 0.1348 mL | 0.6740 mL | 1.3481 mL | 3.3701 mL |
| 20 mM | 0.1011 mL | 0.5055 mL | 1.0110 mL | 2.5276 mL | |
| 25 mM | 0.0809 mL | 0.4044 mL | 0.8088 mL | 2.0221 mL | |
| 30 mM | 0.0674 mL | 0.3370 mL | 0.6740 mL | 1.6851 mL |
BAY1082439 Related Classifications
HY-100886 Related Classifications
Powered by Bioz